Loading...
•
Sep 30
RAPT Q3 2025 Earnings Report
RAPT Therapeutics reported its third quarter 2025 financial results.
Key Takeaways
RAPT Therapeutics reported a net loss of $17.58 million for the third quarter of 2025, an improvement compared to a net loss of $18.432 million in the same period last year. The company highlighted significant progress in its clinical trials, including the initiation of a Phase 2b trial for ozureprubart in food allergy and positive topline data from a Phase 2 trial in chronic spontaneous urticaria. A public offering of $250 million was completed to strengthen the balance sheet, extending the cash runway to mid-2028.
Net loss for Q3 2025 was $17.58 million, an improvement from $18.432 million in Q3 2024.
Initiated prestIgE Phase 2b trial of ozureprubart in food allergy.
Announced positive topline data from Phase 2 trial in chronic spontaneous urticaria, showing comparable efficacy and safety to omalizumab.
Completed a $250 million public offering, projecting to fund operations until mid-2028.
RAPT
RAPT
Forward Guidance
RAPT Therapeutics anticipates continued momentum, with plans to report topline results from Jeyou's Phase 2 trial of ozureprubart in asthma and provide additional details from the Phase 2 CSU trial at a medical meeting next year. The company also intends to engage with regulatory agencies to discuss the registrational pathway for CSU.
Positive Outlook
- Plan to report topline results from Jeyou's Phase 2 trial of ozureprubart in asthma.
- Will provide additional details from the Phase 2 clinical trial in CSU at a medical meeting next year.
- Plan to meet with the FDA and other regulatory agencies to discuss the registrational pathway in CSU.
- Recent financing provides capital to advance programs, including planned initiation of Phase 3 studies of ozureprubart in CSU.
- Strong potential for ozureprubart in large IgE-driven indications like food allergy and CSU.
Challenges Ahead
- No specific negative forward guidance was provided in the report.
- Clinical trial outcomes are inherently uncertain and may not always be positive.
- Regulatory approval processes can be lengthy and unpredictable.
- Reliance on partners and third parties for clinical trial execution.
- Macroeconomic and geopolitical conditions could impact operations.